Cell signaling

Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa® (copanlisib) and rituximab in the U.S. and EU

Retrieved on: 
Monday, June 21, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical trials, Branches of biology, Biology, Oncology, Cell signaling, Programmed cell death, Phosphoinositide 3-kinase, Signal transduction, Kinase, Apoptosis, Phosphoinositide 3-kinase inhibitor, PI3K/AKT/mTOR pathway, Aliqopa® (copanlisib) Injection, non-Hodgkin’s Lymphoma, Oncology at Bayer, Bayer, ALIQOPA® (COPANLISIB) INJECTION, NON-HODGKIN’S LYMPHOMA, ONCOLOGY AT BAYER, BAYER

In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.

Key Points: 
  • In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.
  • Aliqopa is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K- and PI3K- isoforms expressed in malignant B cells.
  • Aliqopa has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines.
  • The clinical development program for Aliqopa also includes the Phase III study CHRONOS-4, evaluating Aliqopa in combination with standard immunochemotherapy in relapsed iNHL.

European Hematology Association - Restoration of T Helper Cell Imbalance in Immune Thrombocytopenia by β2-Adrenergic Receptor Agonists

Retrieved on: 
Friday, June 11, 2021
Branches of biology, Biology, T cells, Cell biology, Immune system, Cell signaling, T helper 17 cell, T helper cell, Platelet, Adrenergic, Adrenergic receptor autoantibodies, CXCL9

Th1 and Th17 subsets are associated with the production of autoantibodies against platelets and restoration of the immune imbalance of Th cells results in clinical improvement.

Key Points: 
  • Th1 and Th17 subsets are associated with the production of autoantibodies against platelets and restoration of the immune imbalance of Th cells results in clinical improvement.
  • Recent studies have demonstrated the presence of 2-adrenergic receptor (2-AR) as the primary adrenergic receptor on immune cells and shown that the nervous system can directly modulate Th cell polarization.
  • Here, we explored the regulation of the sympathetic nervous system on Th cell polarization and the role of 2-AR signaling in immune cell development and pathways during ITP.
  • The Congress is aimed at health professionals working in or interested in the field of hematology.

European Hematology Association - Restoration of T Helper Cell Imbalance in Immune Thrombocytopenia by β2-Adrenergic Receptor Agonists

Retrieved on: 
Friday, June 11, 2021
Branches of biology, Biology, T cells, Cell biology, Immune system, Cell signaling, T helper 17 cell, T helper cell, Platelet, Adrenergic, Adrenergic receptor autoantibodies, CXCL9

Th1 and Th17 subsets are associated with the production of autoantibodies against platelets and restoration of the immune imbalance of Th cells results in clinical improvement.

Key Points: 
  • Th1 and Th17 subsets are associated with the production of autoantibodies against platelets and restoration of the immune imbalance of Th cells results in clinical improvement.
  • Recent studies have demonstrated the presence of 2-adrenergic receptor (2-AR) as the primary adrenergic receptor on immune cells and shown that the nervous system can directly modulate Th cell polarization.
  • Here, we explored the regulation of the sympathetic nervous system on Th cell polarization and the role of 2-AR signaling in immune cell development and pathways during ITP.
  • The Congress is aimed at health professionals working in or interested in the field of hematology.

Live from ASCO 2021 | Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed or Refractory CLL/SLL

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Biology, Programmed cell death, Cell biology, Cellular senescence, Apoptosis, Cell signaling, Immunology, Oncology, Anticancer gene

Patients with CLL or intermediate-high TLS risk were initiated on a daily ramp-up schedule until the dose assigned before the study cycles.

Key Points: 
  • Patients with CLL or intermediate-high TLS risk were initiated on a daily ramp-up schedule until the dose assigned before the study cycles.
  • These patients received a median of 6 cycles (range: 1-24) of treatment with lisaftoclax.
  • Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.
  • Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators.

Aptose to Hold Corporate Update Friday, June 11th

Retrieved on: 
Thursday, May 27, 2021
Enzymes, Branches of biology, Tyrosine kinases, CD135, Acute myeloid leukemia, Cell signaling, Myelodysplastic syndrome, Bruton's tyrosine kinase, Protein kinase inhibitors, Antibody-drug conjugates, Midostaurin, Devimistat

SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress.

Key Points: 
  • SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress.
  • The event will include an up-to-date review of clinical data available for Aptoses clinical programs: luxeptinib (CG-806), Aptoses oral, first-in-class FLT3 and BTK kinase inhibitor in two Phase 1 a/b trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies; and APTO-253, a first-in-class small molecule MYC repressor in a Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndromes (MDS).

C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Medical specialties, Blood, Cell signaling, Programmed cell death, Complement component 4, Complement system, Hematology, Apoptosis

The in vitro results presented confirmed that treatment with CFT7455 results in deep, rapid degradation of IKZF1/3 proteins, generating apoptotic cell death.

Key Points: 
  • The in vitro results presented confirmed that treatment with CFT7455 results in deep, rapid degradation of IKZF1/3 proteins, generating apoptotic cell death.
  • Net loss per share for the first quarter of 2021 was $0.49, compared to $9.59 for the first quarter of 2020.
  • To learn more about C4 Therapeutics, visit www.C4Therapeutics.com .\nThis press release contains \xe2\x80\x9cforward-looking statements\xe2\x80\x9d of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995.
  • All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.\n"

Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Biology, Membrane biology, Organelles, Cell biology, Cell communication, Cell signaling, Systems biology, Vesicle, Biological membrane

These classes of lipid molecules regulate multiple diverse cellular properties and processes, including membrane structure and function, vesicle and organelle trafficking, intracellular signaling and inflammation.

Key Points: 
  • These classes of lipid molecules regulate multiple diverse cellular properties and processes, including membrane structure and function, vesicle and organelle trafficking, intracellular signaling and inflammation.
  • Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements.
  • Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval.
  • Yumanity explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.\n'

JOANN Welcomes Two to Board of Directors, Promotes General Counsel

Retrieved on: 
Tuesday, May 11, 2021
Legal, Public relations, Investor relations, Marketing, Communications, Specialty, Professional services, Home Goods, Search engine marketing, Retail, Online Retail, Drugs, Hudson, Ohio, Jo-Ann Stores, General counsel, Hays, Naloxone, Chemistry, Cell signaling

In another move to strengthen its executive leadership team, JOANN also announces the promotion of its General Counsel.\nAnne Mehlman and Marybeth Hays were nominated to join the Board of Directors as JOANN listed publicly on NASDAQ in March and were confirmed shortly thereafter.

Key Points: 
  • In another move to strengthen its executive leadership team, JOANN also announces the promotion of its General Counsel.\nAnne Mehlman and Marybeth Hays were nominated to join the Board of Directors as JOANN listed publicly on NASDAQ in March and were confirmed shortly thereafter.
  • She is Executive-in-Residence with Kearney consulting, is on the advisory board of Pocket Naloxone, and works with clients through her company, Hays Advising LLC.
  • Prior to joining JOANN, Aber served as Vice President & General Counsel at More Than Gourmet, a specialty food manufacturer.
  • Prior to that, Aber acted as Counsel at Eaton Corporation and was an Associate in the Private Equity practice at Jones Day.

Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021

Retrieved on: 
Thursday, May 6, 2021
Branches of biology, Drugs, NMDA receptor antagonists, Psychoactive drugs, Glutamate, Ionotropic glutamate receptors, Cell signaling, NMDA receptor, N-Methyl-D-aspartic acid, Forward-looking statement, Ketamine, Channel blocker

Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.

Key Points: 
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • No forward-looking statement can be guaranteed, and actual results may differ materially from those projected.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier

Retrieved on: 
Tuesday, May 4, 2021
Branches of biology, Life sciences, Biology, Cell signaling, Drug discovery, Biochemistry, Pharmacology, Receptor, Small molecule

They can arise from either intended or unintended drug-receptor interactions, also known as primary or secondary pharmacology, respectively.

Key Points: 
  • They can arise from either intended or unintended drug-receptor interactions, also known as primary or secondary pharmacology, respectively.
  • Secondary pharmacological profiling is increasingly applied by drug developers and assessed by regulators to evaluate the potential of off-target effects of novel drugs.
  • To address secondary pharmacology, researchers typically screen their small molecule compounds against a broad panel of off-target receptors.
  • \xe2\x80\x9cWith our Secondary Intelligence software, drug developers will be able to make faster, more confident go/no go\xc2\xa0portfolio\xc2\xa0decisions earlier in the drug discovery and development process which will help to increase the likelihood of success in clinical trials.\xe2\x80\x9d\nCertara\xe2\x80\x99s Secondary Intelligence software is the only software that curates and visualizes secondary pharmacology analyses to evaluate safety liabilities against multiple receptors.